Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) Vaccines Purported To Cause Higher Heart Inflammation Among Young Men

The U.S. Centers for Disease Control and Prevention (CDC) have issues with both the Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) vaccines. The organization speaks out on a higher-than-expected number of young men who continue struggling with heart inflammation after the two companies’ intake of the mRNA COVID-19.

CDC and its efforts

The CDC isn’t the only one that has mobilizing resources and relying on top experts to investigate heart inflammation cases. There happen to be several other regulators doing the same thing. Their moves followed shortly after Israel’s Health Ministry came to the limelight to disclose how it had stumbled upon the likely pointer to the condition in the youths that took the vaccines in question.

The agency says that it hasn’t yet concluded the investigation. However, it continues investing time and resources hoping that it will soon finalize and present reliable information. Most people following on the company’s progress closely hoped that it would point out a casual relationship between the cases of myocarditis or pericarditis and the shots.  

Shimabukuro speaks out

A large section of the patients have been hospitalized, and that is unfortunate, according to CDC. However, the agency finds great solace in that most of the patients have recovered fully from the undesirable symptoms.

The deputy director of the CDC’s Immunization Safety Office, Dr. Tom Shimabukuro, states, “We clearly have an imbalance there. The overwhelming majority of the cases have occurred within a week of vaccination.”

The official was presented to the advisory committee of the U.S. Food and Drug Administration during a meeting conducted on Thursday. The second vaccine dose resulted in about  283 observed cases of persons suffering from heart inflammation.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at